DEVELOPMENT AND EVALUATION OF PEDIATRIC DRUG FORMULARY IN TERTIARY CARE HOSPITAL, ERODE.
To develop and evaluate a pediatric hospital formulary in a tertiary care hospital erode. 2)To provide an updated information about the use of medicines to physicians, pharmacists and other healthcare professionals in the hospital for appropriate use of the drugs
The prospective developmental study was carried out in a tertiary care hospital, Erode, Tamil Nadu for a period of six months. A survey was conducted using a validated questionnaire for the identification of the need and content of pediatric formulary among physicians in the hospital.The pediatric formulary was developed and the quality was evaluated using a validated questionnaire form.The content of the formulary was framed based on the opinion of physicians.
The prepared pediatric formulary was assessed with the validated feedback questionnaire. Out of 58 doctors 50 (86.2%) doctors were satisfied with the developed formulary for about 29 (50%) doctors formulary was very useful in their clinical practice and. The necessity of pediatric formulary was supported by 80 % of physcians at first but after the implementation of formulary 86% were highly satisfied with the formulary and appreciated the work that was carried out to a great level.
Â The formulary was handy, user friendly and saves the precious time of busy physician. It may also promotesthe safe and effective use of medicines thereby minimizing drug related problems in pediatric population.
Â Key words: Formulary, paediatrics, clinical practice.
2. World Health Organization. Promoting safety of medicines for children. WHO, Geneva, 2007.
3. Boelsterli UA. Mechanisms of NSAID-induced hepatotoxicity: focus on nimesulide. Drug Saf. 2002; 25(2): 633-648.
4. Ramadaniat HU, Tambunan T, Khairani S, Adisty HS. Off-label and unlicensed prescribing in pediatric inpatients with nephritic syndrome in a major teaching hospital: an Indonesian context. Asian J Pharm Clin Res. 2017; 10(1): 355-359.
5. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology: drug disposition, action and therapy in infants and children. N Engl J Med. 2003; 349(12): 1157â€“1167.
6. Horen B, Montastruc JL, LapeyreMestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol. 2002; 54(6): 665â€“670.
7. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: Prospective study. Br Med J. 1998; 316(7128): 343â€“345.
8. Napoleone E. Children and ADRs (adverse drug reactions). Ital J Pediatr. 2010; 36(1): 4.
9. Almeida RJ, Acharya LD, Rao PG, Jose J, Bhat RY. Development of Hospital formulary for a tertiary care teaching hospital in South India. Indian J Pharm Sci. 2007; 69(6): 773-779.
10. Roberts R, Rodriguez W, Murphy D, Crescenzi T. Pediatric Drug Labeling: Improving the Safety and Efficacy of Pediatric Therapies. JAMA. 2003; 290(7): 905-911.
11. Jong WT, Vulto A, DeHoog M, Schimmel KJ, Tibboel D, Van den Anker JN. Unapproved and off label use of drugs in a children's hospital. N Engl J Med. 2000; 343(15): 1125.
12. Committee on Drugs. Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.Pediatrics.1996; 98(1): 143-145.
13. Gravilov V, Lifskitz M, Levy J, Gorodischer R. Unlicensed and "off label" medication use in a general pediatrics ambulatory hospital unit in Israel. Isr Med Assoc J. 2000; 2(1): 595-597.
14. Avenel S, Bomkratz A, Dassieu G, Janaud JC, Danan C. The incidence of prescriptions without marketing product license in a neonatal intensive care unit. Arch Pediatr. 2000; 7(2): 143-147.
15. Rashed AN, Neubert A, Tomlin S, Jackman J, AlhamdanH, Alshaikh A et al. Epidemiology and potential associated risk factors of drug-related problems in hospitalized children in the United Kingdom and Saudi Arabia. Eur J Clin Pharmacol. 2012; 68(12): 1657â€“1666.
16. Blix HS, Viktil KK, Mger TA, Reikvam A. Characteristics of drug-related problems discussed by hospital pharmacists in multidisciplinary teams. Pharm World Sci. 2006; 28(3): 152â€“158.
17. Ibrahim N, Wong IC, Patey S, Tomlin S, Sinha MD, Jani Y.Drug-related problem in children with chronic kidney disease. Pediatr Nephrol. 2013; 28(1): 25â€“31.
18. Easton KL, Chapman CB, Brien JA. Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. Br J Clin Pharmacol. 2004; 57(5): 611â€“615.
19. Rashed AN, Neubert A, Alhamdan H, Tomlin S, Alazmi A, Alshaikh A, et al. Drug-related problems found in children attending an emergency department in Saudi Arabia and in the United Kingdom. Int J Clin Pharm. 2013; 35(3): 327â€“331.
20. Brunlof G, Tukukino C, Wallerstedt SM. Individual case safety reports in children in commonly used drug groups-signal detection. BMC Clin Pharm. 2008; 8(1): 1-5.
21. Berry MA, Shah PS, Brouillette RT, Hellmann J. Predictors of mortality and length of stay for neonates admitted to children's hospital neonatal intensive care units. J Perinatol. 2008; 28(4): 297â€“302.
22. Neubert A, Dormann H, Weiss J, Egger T, Criegee-Rieck M, Rascher W, Brune K, HinzB. The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients. Drug Saf. 2004; 27(13): 1059â€“1067.
23. Lassetter JH, Warnick ML. Medical errors, drug-related problems, and medication errors: a literature review onquality of care and cost issues. J Nurs Care Qual. 2003; 18(3): 175â€“181.
24. Einarson TR. Drug-related hospital admissions. Ann Pharmacother.1993; 27(7): 832â€“840.
25. Moore TJ, Weiss SR, Kaplan S, Blaisdell CJ. Reported adverse drug events in infants and children under 2 years of age. Pediatrics. 2002; 110(5): e53.
26. Priyadharsini R, Surendiran A, Adithan C, Sreenivasan S, Sahoo FK. A study of adverse drug reactions in pediatric patients. J Pharmacol Pharmacother. 2011; 2(4): 277-280.